Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II neoadjuvant gemcitabine + erlotinib followed by gemcitabine + erlotinib + radiotherapy in resectable pancreatic adenocarcinoma
2010-021738-72Phase 2Active
- Sponsor
- GEMCAD
- Start
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and erlotinib in pancreatic adenocarcinoma (PDAC), sponsored by GEMCAD. Primary endpoint: R0 resection rate. Started Jul 2010; status: active.
02
Drugs
gemcitabineerlotinib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2010-021738-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021738-72.